Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

NCT01403311 is registered in ClinicalTrials.gov with Legacy Health System as lead sponsor.

NCT NCT01403311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01403311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain
Lead sponsor
Legacy Health System
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2010
Completion date
March 31, 2015
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma